Undercovered Dozen: Dynex Capital, Blackstone, Rithm Capital, And More
The Undercovered Dozen series spotlights 12 lesser-covered stocks featured on Seeking Alpha between June 5 and June 11. This curated selection aims to provide fresh investment ideas and foster community discussion around under-the-radar equities. Readers are encouraged to engage, share perspectives, and highlight additional overlooked investment opportunities.
Apogee Therapeutics Maps Phase 3 Push for Zumilokibart, Backed by Blackstone Funding
Apogee Therapeutics NASDAQ: APGE executives outlined plans to advance zumilokibart, the company's IL-13-targeting antibody, into late-stage development for atopic dermatitis while expanding the program into asthma and eosinophilic esophagitis, during a Goldman Sachs discussion hosted by lead biotechnology equity research analyst Salveen Richter.
Blackstone: The Market Is Selling Over A Problem That Doesn't Exist
Blackstone Inc. (BX) is rated a Buy, offering quality growth at discounted valuations despite sector-wide private credit concerns. BX's diversified model, robust credit underwriting, and focus on investment-grade secured debt position it to absorb private credit shocks better than peers. Key growth catalysts in AI/data center infrastructure, 401(k) regulatory changes, and perpetual capital, are not fully priced into BX shares.
Blackstone Inc. (BX) Presents at Morgan Stanley US Financials Conference 2026 Transcript
Blackstone Inc. (BX) Presents at Morgan Stanley US Financials Conference 2026 Transcript
Blackstone: One Of The Best Opportunities Of The Decade
BX's stock price has recently dropped by nearly 40%. And it left investors wondering whether it's time to sell or buy even more. BX's fundamentals don't justify the sell-off, as its inflows, fee growth, AUM, and other key metrics were either record-level or very strong. The market is wrong about BX being a victim of AI. In fact, it's one of the beneficiaries.
Blackstone restricts flagship fund withdrawals as private asset fears reemerge
Blackstone restricts flagship fund withdrawals as private asset fears reemerge
Apogee Therapeutics Readies Zumi for Phase 3 With Blackstone Backing
Apogee Therapeutics NASDAQ: APGE executives said the company is preparing to move its lead drug candidate, zumilokibart, into Phase 3 testing later this year after reporting Phase 2b data in atopic dermatitis and securing a major financing agreement with Blackstone.
Blackstone Raises $13.1 Billion in Its Largest Asia Private-Equity Fund
The New York-based alternative asset manager raised more than the $10 billion target for the Blackstone Capital Partners Asia III fund.
Apollo, Blackstone work on $36 billion debt deal for Anthropic, Bloomberg News reports
Apollo Global Management and Blackstone are working to bring in additional investors for about $36 billion debt financing tied to AI startup Anthropic PBC's efforts to expand its AI infrastructure, Bloomberg News reported on Thursday.
AI Consolidation Begins: Blackstone & Google Forge an AI Empire
The artificial intelligence infrastructure buildout is entering its consolidation phase. In a decisive move that reshapes the competitive landscape, private equity giant Blackstone NYSE: BX and hyperscaler Alphabet NASDAQ: GOOGL announced a $5 billion joint venture to create a new AI cloud platform.
IX or BX: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Financial - Miscellaneous Services sector have probably already heard of Orix (IX) and Blackstone Inc. (BX). But which of these two stocks offers value investors a better bang for their buck right now?
Blackstone and Google form AI infrastructure joint venture focused on TPU cloud expansion
Blackstone Inc (NYSE:BX) and Alphabet's Google have announced a joint venture aimed at developing a new US-based company that will provide dedicated cloud infrastructure centered on Google's Tensor Processing Units (TPUs). The planned company will offer data center capacity, operations, networking, and TPUs as a compute-as-a-service platform, giving customers an alternative way to access Google's AI-optimized chips outside of Google Cloud.
